Idiopathic Pulmonary Fibrosis Market Expands as Novel Therapies Reshape Treatment

Idiopathic Pulmonary Fibrosis Market Overview and Disease Burden

Idiopathic pulmonary fibrosis (IPF) is a progressive and irreversible respiratory disorder marked by extensive scarring of lung tissue, gradually impairing breathing capacity and pulmonary function. The idiopathic pulmonary fibrosis market continues to attract significant attention because available treatments can slow functional deterioration but cannot reverse established fibrosis. DelveInsight estimates that approximately 300,000 diagnosed prevalent IPF cases were recorded across the 7MM in 2025, while the market was valued at nearly USD 3.3 billion in 2023. The assessment covers the United States, EU4, the United Kingdom, and Japan through 2036.

Idiopathic Pulmonary Fibrosis Treatment Market and Existing Therapies

The idiopathic pulmonary fibrosis treatment market is evolving as researchers and healthcare professionals pursue therapies capable of delivering improved disease control, tolerability, and long-term outcomes. Pharmacological treatment remains centered on antifibrotic medicines, supported by symptom management and other supportive-care interventions.

Nintedanib and pirfenidone have historically formed the foundation of pharmacological IPF management. More recent developments have introduced additional options, including JASCAYD (nerandomilast), while established therapies such as ESBRIET (pirfenidone) and OFEV (nintedanib) continue to be important in clinical practice. Although these treatments can slow lung-function decline, they do not cure IPF. Gastrointestinal complications and other tolerability concerns associated with existing therapies continue to create opportunities for treatments with improved safety and convenience.

Idiopathic Pulmonary Fibrosis Market Size and Regional Landscape

The ipf market size demonstrates a substantial commercial opportunity across the major pharmaceutical markets. According to DelveInsight, the 7MM IPF market generated approximately USD 3.3 billion in 2023 and is projected to expand throughout the forecast period.

The United States represents the largest individual market, supported by a sizeable diagnosed population, advanced healthcare infrastructure, specialist availability, and relatively strong treatment adoption. In 2025, approximately 125,000 diagnosed prevalent cases were estimated in the US, accounting for around 41% of the total 7MM population. EU4 and the UK collectively represented another approximately 41%, while Japan accounted for nearly 18%.

US Idiopathic Pulmonary Fibrosis Treatment Market and Growth Potential

The us idiopathic pulmonary fibrosis treatment market is positioned to remain a major contributor to global market expansion. An aging population, greater disease awareness, improved diagnostic capabilities, and continued pharmaceutical innovation are among the factors supporting its development.

Accurate diagnosis remains particularly important because IPF symptoms can resemble those of other respiratory disorders. High-resolution computed tomography, pulmonary function testing, laboratory assessments, and, in selected circumstances, lung biopsy can assist clinicians in establishing a diagnosis. Improvements in diagnostic pathways and greater physician awareness may enable earlier identification of patients and increase opportunities for timely disease management.

Idiopathic Pulmonary Fibrosis Market and Emerging Therapeutic Innovation

The pipeline is becoming an increasingly important component of the future idiopathic pulmonary fibrosis market. Drug developers are investigating mechanisms associated with fibrosis, inflammation, cellular signaling, and other biological processes involved in disease progression.

DelveInsight highlights emerging candidates such as pamrevlumab, inhaled treprostinil (Tyvaso), C21, PLN-74809, BI 1015550, and BMS-986278. These programs demonstrate the industry's focus on developing differentiated approaches that could complement or improve upon existing antifibrotic treatment.

Regulatory and clinical developments are also contributing to optimism surrounding the pipeline. The approval of JASCAYD (nerandomilast) in the United States in October 2025 represented a notable addition to the IPF treatment landscape. In December 2025, PureTech announced a successful FDA End-of-Phase II meeting for deupirfenidone (LYT-100), with the Phase III SURPASS-IPF study planned for 2026. Such developments highlight the continued push toward therapies with potentially differentiated efficacy and tolerability profiles.

Fibrotic Diseases Treatment Market and Broader Opportunities

The fibrotic diseases treatment market is attracting increasing research interest as scientists investigate biological mechanisms shared across multiple progressive fibrotic disorders. IPF is particularly significant because its irreversible progression and limited therapeutic options create considerable demand for treatments capable of slowing or potentially modifying disease progression.

Advances in molecular profiling, biomarkers, genetics, and disease characterization may improve patient identification and support more personalized treatment strategies. Research presented at the 2024 American Thoracic Society conference explored areas including biomarkers, circulating proteomes, differentiation of fibrotic hypersensitivity pneumonitis from IPF, and methods for predicting disease characteristics and severity.

Idiopathic Interstitial Pneumonias Market and Persistent Unmet Needs

The idiopathic interstitial pneumonias market encompasses a broader group of interstitial lung disorders, with IPF representing one of the most clinically significant progressive fibrotic diseases. Despite improvements in diagnosis and antifibrotic treatment, considerable unmet needs remain.

Delayed diagnosis, progressive loss of lung function, lack of curative treatment, treatment-related tolerability issues, and high mortality continue to present challenges. Future therapies will need to demonstrate meaningful improvements in preserving pulmonary function while potentially offering better safety, quality of life, disease control, and survival outcomes.

Treatments capable of addressing shortcomings associated with current antifibrotic medicines could achieve significant differentiation in both clinical practice and the competitive landscape.

Idiopathic Pulmonary Fibrosis Market Outlook Through 2036

The future of IPF treatment is being shaped by the combination of rising epidemiological demand, therapeutic innovation, and improved recognition of the disease. DelveInsight's forecast evaluates the United States, EU4, the UK, and Japan through 2036, examining patient epidemiology and market performance across therapies and drug classes.

An aging population is expected to remain an important market driver, while better diagnostic approaches could identify patients who previously remained undiagnosed. At the same time, reimbursement policies, regulatory decisions, treatment accessibility, and healthcare-system adoption will influence the commercial performance of emerging therapies.

As more late-stage candidates advance, competition is likely to intensify. Developers that can demonstrate durable lung-function preservation, improved tolerability, convenient administration, and meaningful patient benefits may be better positioned to establish a differentiated role in future treatment algorithms.

Conclusion

The IPF treatment landscape is undergoing meaningful transformation as pharmaceutical innovation advances alongside improved disease recognition and diagnostic capabilities. Established antifibrotic therapies remain important for slowing disease progression, but persistent limitations continue to create opportunities for novel treatments. New approvals and advancing pipeline programs could expand therapeutic choices and introduce greater competition across major markets. Continued investment in biomarkers, precision medicine, disease-modifying mechanisms, patient stratification, and better-tolerated therapies will be essential for addressing unmet needs and improving outcomes.

Latest Reports by DelveInsight:

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact

Company Name: DelveInsight Business Research LLP

Contact Person: Abhishek kumar

Email: abhishek@delveinsight.com

City: Albany

State: New York

Country: United States

Website: https://www.delveinsight.com

Share: